Global, regional, and national burden of HIV/AIDS, 1990–2021, and forecasts to 2050, for 204 countries and territories: the Global Burden of Disease Study 2021
Austin Carter, Meixin Zhang, Khai Hoan Tram et al. · The Lancet HIV · 2024
Full textCC BY
Infectious Diseases
Filters3 filters applied
Status
- Expression of concern
- Corrected
- No notice
- From publisher notices and Retraction Watch. Not checked means nobody has looked yet.
Year
Readable here
Study type
Licence
Prevalence of persistent SARS-CoV-2 in a large community surveillance study
Mahan Ghafari, Matthew Hall, Tanya Golubchik et al. · Nature · 2024
Full textCC BY
Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion
Delphine Planas, Isabelle Staropoli, Vincent Michel et al. · Nature Communications · 2024
Full textCC BY
Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets
Shahinda S. R. Alsayed, Hendra Gunosewoyo · International Journal of Molecular Sciences · 2023 · Review
Full textCC BY
Clinical Impact of Staphylococcus aureus Skin and Soft Tissue Infections
Matthew S. Linz, Arun Mattappallil, Diana Finkel et al. · Antibiotics · 2023 · Review
Full textCC BY
Bile salt hydrolases shape the bile acid landscape and restrict Clostridioides difficile growth in the murine gut
Matthew H. Foley, Morgan E. Walker, Allison K. Stewart et al. · Nature Microbiology · 2023
Full textCC BY
The development of COVID-19 treatment
Yongliang Yuan, Baihai Jiao, Lili Qu et al. · Frontiers in Immunology · 2023 · Review
Full textCC BY
Antifungal Drug Resistance: An Emergent Health Threat
Antonio Vitiello, Francesco Ferrara, Mariarosaria Boccellino et al. · Biomedicines · 2023 · Review
Full textCC BY
Diagnosis of invasive fungal infections: challenges and recent developments
Wenjie Fang, Junqi Wu, Mingrong Cheng et al. · Journal of Biomedical Science · 2023 · Review
Full textCC BY
Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity
Francesco Menegale, Mattia Manica, Agnese Zardini et al. · JAMA Network Open · 2023 · Meta-analysis
Full textCC BY
The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
Dirk Jochmans, Cheng Liu, Kim Donckers et al. · mBio · 2023
Full textCC BY
Pathogenicity and virulence of Mycobacterium tuberculosis
Kathryn C. Rahlwes, Beatriz R.S. Dias, Priscila C. Campos et al. · Virulence · 2023 · Review
Full textCC BY
Learning from prepandemic data to forecast viral escape
Nicole N. Thadani, Sarah Gurev, Pascal Notin et al. · Nature · 2023
Full textCC BY
TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry
Jim Baggen, Maarten Jacquemyn, Leentje Persoons et al. · Cell · 2023
Full textCC BY
Percentage of Asymptomatic Infections among SARS-CoV-2 Omicron Variant-Positive Individuals: A Systematic Review and Meta-Analysis
Weijing Shang, Liangyu Kang, Guiying Cao et al. · Vaccines · 2022 · Review
Full textCC BY
Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons
Philip L. Tzou, Kaiming Tao, Sergei L. Kosakovsky Pond et al. · PLOS ONE · 2022
Full textCC BY
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
Juliet R. C. Pulliam, Cari van Schalkwyk, Nevashan Govender et al. · Science · 2022
Full textCC BY
Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 Omicron BA.1
Alief Moulana, Thomas Dupic, Angela M. Phillips et al. · Nature Communications · 2022
Full textCC BY
An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain
Allison J Greaney, Tyler N Starr, Jesse D Bloom · Virus Evolution · 2022
Full textCC BY
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
William A. Fischer, Joseph J. Eron, Wayne Holman et al. · Science Translational Medicine · 2022
Full textCC BY